• 4-13 × 10⁶ cells/mL dispersion for infusion
• Approved for treating transfusion-dependent beta-thalassaemia in people 12 years and over in line with NICE

• For the treatment of iron deficiency anemia in patients with or without inflammatory bowel disease.


• To be initiated by specialist in inflammatory bowel disease or iron deficiency anaemia 

• First Choice oral liquid iron preparation - 140mg in 5ml syrup (45mg iron/5ml).
• 210mg tablets (68mg iron/tablet).

300mg tablets (35mg iron)

• 190mg in 5ml sugar-free elixir (27.5mg iron/5ml).

• For use as an alternative to iron dextran or iron sucrose. Approved for
  use by renal physicians, gastroenterologists and haematologists.
• Unlicensed for use in children under 14 years of age. If used in this age-group, use should only be on the advice of a consultant with the informed consent of the patient and/or his/her parents/carers.

Solution for injection: 100 mg/2 mL

• 400 microgram and 5mg tablets
• 2.5mg in 5ml sugar-free syrup
• 15mg in 1ml injection unlicensed
• 30mg in 2ml injection

• 340 mg solution for injection/infusion
• Approved as an option for treating paroxysmal nocturnal haemoglobinuria in people 12 years and over who weigh 40 kg or more in line with NICE

• 50mg, 100mg tablets
• Approved as an add-on to ravulizumab or eculizumab as an option for treating paroxysmal nocturnal haemoglobinuria (PNH) in adults who have residual haemolytic anaemia in line with NICe

Paroxysmal nocturnal haemoglobinuria treatment is only commissioned from:

• King’s College Hospital NHS Foundation Trust, London - London and South East
• Leeds Teaching Hospitals NHS Trust - Rest of United Kingdom

• 300mg/30ml solution for infusion
• Approved treating atypical haemolytic uraemic syndrome in adults and children in line with NICE

Paroxysmal nocturnal haemoglobinuria treatment is only commissioned from:

• King’s College Hospital NHS Foundation Trust, London - London and South East
• Leeds Teaching Hospitals NHS Trust - Rest of United Kingdom

• 200mg hard capsules
• Approved for treating paroxysmal nocturnal haemoglobinuria (PNH) in adults with haemolytic anaemia in line with NICE

Paroxysmal nocturnal haemoglobinuria treatment is only commissioned from:

• King’s College Hospital NHS Foundation Trust, London - London and South East
• Leeds Teaching Hospitals NHS Trust - Rest of United Kingdom

• 1080mg/20 solution for infusion
• Approved for the treatment paroxysmal nocturnal haemoglobinuria in adults who have anaemia after at least 3 months of treatment with a C5 inhibitor in line with NICE and NHSE Commissioning Policy.

• Paroxysmal nocturnal haemoglobinuria treatment is only commissioned from:
  
  • King’s College Hospital NHS Foundation Trust, London - London and South East
  • Leeds Teaching Hospitals NHS Trust - Rest of United Kingdom

• 300mg/30ml & 1,100mg/11ml concentrate for solution for infusion
• Approved for the treatment of paroxysmal nocturnal haemoglobinuria in adults in line with NICE
• Approved for the treatment of atypical haemolytic uraemic syndrome in line with NICE
• Paroxysmal nocturnal haemoglobinuria treatment is only commissioned from 
  
  • King’s College Hospital NHS Foundation Trust, London - London and South East
  • Leeds Teaching Hospitals NHS Trust - Rest of United Kingdom

• 20mg, 50mg, 70mg, 100mg and 150mg tablets
• Approved for treating symptomatic anaemia associated with chronic kidney disease in adults in line with NICE

• 150mg, 300 mg film coated tablets
• Approved as an option for treating symptomatic anaemia caused by chronic kidney disease in adults having maintenance dialysis in line with NICE

• Prefilled syringes (various strengths)
  
  • Approved for management of cancer treatment-induced anaemia in
    women receiving platinum-based chemotherapy for ovarian cancer
  • No longer regularly used in NUTH

• Cartridges for use in RecopensPrefilled syringes
  
  
  
  
  • Approved for management of cancer treatment-induced anaemia
    in women receiving platinum-based chemotherapy for ovarian cancer.
  
  
  • No longer regularly used in NUTH.
  
  
  
  


• Monitoring: monitoring of erythropeoetin (epoetin beta) in adult patients can be undertaken by GPs under a shared care arrangement 

• 30, 50, 100, 120, 150, 200 & 250 microgram in 0.3ml and 360 microgram in 0.6ml injections in prefilled syringes.
• Approved for use as a longer-acting alternative to darbepoetin in a
  small number of patients receiving peritoneal dialysis.

• Approved for iron chelation in patients with myelodysplastic syndromes (MDS) - (as per NECN Haematology Group Guidelines) and recommended for use in patients when treatment with desferrioxamine is no longer considered to be appropriate due to progressive iron overload despite maximally tolerated doses of desferrioxamine. 
• Approved for the treatment of iron overload for trasnfused and non-tranfused patients with chronic inherited anaemias (all ages) in line with NHSE Specialised Commissioning Policy

• Approved for the treatment of iron overload for trasnfused and non-tranfused patients with chronic inherited anaemias (all ages) in line with NHSE Specialised Commissioning Policy

• For the treatment of thrombocythemiaas a 2nd line agent in patients poorly/non-responsive tohydroxycarbamide therapy.

• Approved for the treatment of severe thrombocytopenia in people with chronic liver disease needing a planned invasive procedure in line with NICE
• Approved for treating primary chronic immune thrombocytopenia in adults in line with NICE

• 10mg solution for injection
  
  
  
  • Approved with plasma exchange and immunosuppression for treating acute acquired thrombotic thrombocytopenic purpura in adults, and in young people aged 12 years and over who weigh at least 40 kg in line with NICE
  
  
  
  

• For the treatment of adults with chronic immune (idiopathic) thrombocytopenia purpura in line with NICE.

• 3mg film-coated tablets


• Approved as an option for treating severe thrombocytopenia in adults with chronic liver disease having planned invasive procedures in line with NICE

• For the treatment of adults with chronic immune (idiopathic) thrombocytopenia purpura in line with NICE.

• Available as Neupogen (original brand) and Ratiograstim – a
  biosimilar product.

• 263 microgram (33.6 million units) injection vials

• Approved by NHS England Specialist Services for stem cell mobilisation for patients with Hodgkin’s disease, Non-Hodgkins lymphoma or multiple myeloma and meet the policy for Haematopoietic Stem Cell Transplantation.
• Note that there are no commissioned providers in NEY region.